At the leading edge of biology and assay technology, Singlera Genomics uses a new biomarker type called ctmDNA (circulating tumor methylated DNA) to peer into the future. Targeted methylation approaches have historically not been developed due to technical hurdles. Singlera announces a unique approach, examining methylation haplotypes (adjacent methylation sites on the same contiguous strand of DNA) from cell-free DNA as a method for cancer biomarker detection. By using a highly specific and targeted methylation enrichment method, both the overall sample input requirement is lowered and the overall amount of sequencing necessary for excellent sensitivity is reduced.